New aspects of photodynamic therapy for central type early stage lung cancer

2011 ◽  
Vol 43 (7) ◽  
pp. 749-754 ◽  
Author(s):  
Norihiko Ikeda ◽  
Jitsuo Usuda ◽  
Harubumi Kato ◽  
Taichiro Ishizumi ◽  
Shuji Ichinose ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Photodynamic Therapy ◽  
Early Stage ◽  
Early Stage Lung Cancer ◽  
Central Type ◽  
Stage Lung Cancer

Locally Recurrent Central-Type Early Stage Lung Cancer < 1.0 cm in Diameter After Complete Remission by Photodynamic Therapy

CHEST Journal ◽  
2005 ◽  
Vol 128 (5) ◽  
pp. 3269-3275 ◽  
Author(s):  
Kinya Furukawa ◽  
Harubumi Kato ◽  
Chimori Konaka ◽  
Tetsuya Okunaka ◽  
Jituo Usuda ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Photodynamic Therapy ◽  
Complete Remission ◽  
Early Stage ◽  
Early Stage Lung Cancer ◽  
Central Type ◽  
Locally Recurrent ◽  
Stage Lung Cancer

scholarly journals Photodynamic Therapy of Lung Cancer With Bronchial Artery Infusion of Photofrin

1996 ◽  
Vol 2 (4) ◽  
pp. 203-206 ◽  
Author(s):  
Tetsuya Okunaka ◽  
Harubumi Kato ◽  
Chimori Konaka ◽  
Kinya Furukawa ◽  
Masahiko Harada ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Photodynamic Therapy ◽  
Early Stage ◽  
Bronchial Artery ◽  
Arterial Infusion ◽  
Early Stage Lung Cancer ◽  
Hospitalization Period ◽  
Bronchial Arterial Infusion ◽  
Skin Photosensitivity ◽  
Stage Lung Cancer

Photodynamic therapy (PDT) utilizing Photofrin is proving to be effective for the treatment of early stage lung cancer. However, wider clinical applications of Photofrin as a photosensitizer for various cancers are hampered by potentially serious and prolonged skin photosensitivity. To prevent these side effects and reduce the hospitalization period, we recently gave reduced doses of Photofrin by bronchial arterial infusion. Five patients with endoscopically evaluated minimally invasive carcinoma of the lung were given 0.7 mg/kg of Photofrin by bronchial arterial infusion 48 hr before PDT. Complete remission was obtained in all 5 cases and no case showed skin photosensitivity when exposed to sunlight under careful surveillance at one week after PDT.

Photodynamic therapy using Laserphyrin for centrally located early stage lung cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 7229-7229 ◽  
Author(s):  
J. Usuda ◽  
H. Kato ◽  
T. Okunaka ◽  
K. Furukawa ◽  
H. Honda ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Photodynamic Therapy ◽  
Early Stage ◽  
Stage I ◽  
University Hospital ◽  
Early Stage Lung Cancer ◽  
Endobronchial Ultrasonography ◽  
Tokyo Medical ◽  
Medical University ◽  
Stage Lung Cancer

7229 Background: In central type early stage lung cancer, the tumor must be located only as far as the segmental bronchi and be carcinoma in situ or with only limited invasion into the bronchial wall. Laserphyrin (mono-L-aspartyl chlorine e6, NPe6) is a second generation photosensitize and approved by the Japanese government and has been on sale from June 2004. Methods: Four h after the administration of Laserphyrin 40 mg/m2, we irradiated using diode laser (100 mJ/cm2). Before PDT, we evaluated the tumor lesions and tumor depth using autofluorescence bronchoscopy and endobronchial ultrasonography (EBUS), and we confirmed the area of laser irradiation. Results: From February 1980 to December 2005, a total number of 204 patients with 264 lesions of centrally located early stage lung cancer underwent photodynamic therapy (PDT) in the Department of Thoracic Surgery, Tokyo Medical University Hospital. There were 185 clinical stage 0 lesions and 79 stage I lesions. CRs and PRs were obtained in 224 lesions (84.8%) and 40 lesions (15.2%) out of 264 lesions. From July 2004 to December 2005, we performed Laserphyrin-PDT for 28 lesions of centrally located early stage lung cancer in Tokyo Medical University Hospital. The rate of CR was 92.9% (26 lesions) in 28 lesions. For Laserphyrin-PDT, Skin photosensitivity was very low and the clean-up bronchoscopies were not frequently needed, and the period of hospitalization was shorter compared to that for Photofrin-PDT. Conclusions: We conclude that PDT using Laserphyrin will be a standard option for stage 0 (TisN0M0) and stage I (T1N0M0) centrally located early stage lung cancer. No significant financial relationships to disclose.

scholarly journals Effects of Photodynamic Therapy in Inoperable Early Stage Lung Cancer Patients.

Haigan ◽  
1995 ◽  
Vol 35 (2) ◽  
pp. 127-132
Author(s):  
Naofumi Takehara ◽  
Yoshinobu Ohsaki ◽  
Satoru Fujiuchi ◽  
Shuji Yamaguchi ◽  
Yuji Akiba ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Photodynamic Therapy ◽  
Cancer Patients ◽  
Early Stage ◽  
Early Stage Lung Cancer ◽  
Lung Cancer Patients ◽  
Stage Lung Cancer

scholarly journals A case of central type early stage lung cancer receiving 60Co high dose-rate postoperative endobronchial radiation.

Haigan ◽  
1985 ◽  
Vol 25 (4) ◽  
pp. 543-548
Author(s):  
Syouji Nakamori ◽  
Ken Kodama ◽  
Eiji Kurokawa ◽  
Osamu Doi ◽  
Toshio Terasawa ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Dose Rate ◽  
Early Stage ◽  
High Dose Rate ◽  
High Dose ◽  
Early Stage Lung Cancer ◽  
Central Type ◽  
Stage Lung Cancer

A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer. The Japan Lung Cancer Photodynamic Therapy Study Group.

1993 ◽  
Vol 11 (10) ◽  
pp. 1852-1857 ◽  
Author(s):  
K Furuse ◽  
M Fukuoka ◽  
H Kato ◽  
T Horai ◽  
K Kubota ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Photodynamic Therapy ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Early Stage ◽  
Dye Laser ◽  
Arterial Oxygen ◽  
Early Stage Lung Cancer ◽  
Photofrin Ii ◽  
Stage Lung Cancer

PURPOSE A phase II study was conducted between June 1989 and February 1992 to evaluate the activity and toxicity of photodynamic therapy (PDT) with photofrin II in centrally located early-stage lung cancer and to determine the complete response (CR) rate as the primary end point. PATIENTS AND METHODS Patients had histologically proven lung cancer and endoscopically superficial thickening or small protrusions. All lesions were located in subsegmental or larger bronchi. All patients had a performance status (PS) of 0 to 2 and arterial oxygen pressure tension (PaO2) > or = 60 mm Hg. No lymph node or distant metastases were present. All patients received photofrin II (2 mg/kg) intravenously 48 hours before PDT. Tumor lesions were superficially photoradiated by an argon dye laser or an excimer dye laser. RESULTS Of 54 patients with 64 carcinomas, 51 with 61 carcinomas were eligible for toxicity evaluation and 49 with 59 carcinomas were assessable for response. Of the 59 assessable carcinomas, 50 (84.8%; 95% confidence interval, 73.0% to 92.8%) showed a CR after initial PDT. The median duration of CR was 14.0+ months (range, 2.0+ to 32.4+). The multiple regression model indicates that estimated length of longitudinal tumor extent was the only independent prognostic factor for CR (P = .002). Five carcinomas that had a CR had a local recurrence at 6, 10, 12, 16, and 18 months after initial PDT, respectively. Toxicity assessment (World Health Organization [WHO] grade 2) showed transient elevation of ALT (1.9%), pulmonary toxicity (7.7%), and allergic reaction (7.7%), as well as sunburn (1.9%). CONCLUSION PDT with photofrin II has an excellent effect on patients with centrally located early-stage lung cancer who have limited tumor invasion extending over a small area (< or = 1 cm).

Sign in / Sign up

Export Citation Format

Share Document